Dr Scott Smid
Senior Lecturer
School of Biomedicine
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Dr Scott Smid is a pharmacologist specializing in drug discovery and development research both in industry and academia. He maintains a strong research interest in experimental therapeutics applied towards novel treatments for gastrointestinal and neurodegenerative diseases. This includes investigating the biological actions of phytocannabinoids, synthetic cannabinoids and endocannabinoids in areas as diverse as gut function, inflammation and neurodegeneration. Current interests include novel ligand development for binding and inhibiting pathological aggregating proteins such as beta-amyloid and alpha-synuclein, which are associated with Alzheimer's and Parkinson's disease.
- My Research
- Career
- Publications
- Grants and Funding
- Teaching
- Supervision
- Professional Activities
- Contact
Current projects for Masters, M.Phil or PhD candidates include:
1. Identifying novel cannabis phytochemicals with neuroprotective properties. This includes using neural stem cells and other neuronal cell populations to model neurotoxicity to dementia-associated misfolding proteins such as amyloid beta and alpha-synuclein, related to Alzheimer's and Parkinson's disease. We have identified a range of cannabis phytochemicals with bioactive properties, including novel phytocannabinoids, selected terpenes and a novel cannabis flavonoids with neuroprotective activity that could be used in nutritional or nutraceutical settings in ageing.
2. Identifying and characterising novel cannabis phytochemicals and derivatives with chemotherapeutic properties, including antibiotic bioactivity. The non-psychotropic component of cannabis, cannabidiol (CBD) and its derivatives have bacteriostatic and bacteriocidal activity against a range of Gram-positive bacteria, but also has been shown to arrest cell growth and division in human malignant cell lines via undefined mechanisms. This may enable further use of CBD and derivatives as adjunctive or standalone treatments in cancer.
3. Identifying and characterising diverse and novel natural products and constituent polyphenols with gastro- and neuro-protective properties, including intestinal barrier function and antimicrobial activity. This includes recent and previous research including international collaborations using seaweeds, grape skin, tea, acai and Goji berry to name a few.
-
Appointments
Date Position Institution name 2015 - ongoing Visiting Fellow University of Western Australia, Perth 2012 - ongoing Deputy Head University of Adelaide, Adelaide 2006 - ongoing Senior Lecturer University of Adelaide, Adelaide -
Awards and Achievements
Date Type Title Institution Name Country Amount 2012 Award Faculty International Conference Award (FICA) - - - -
Education
Date Institution name Country Title 1991 - 1994 University of Adelaide, Adelaide Australia Doctor of Philosophy 1990 University of Adelaide, Adelaide Australia Honours Degree of Bachelor of Science (Class 1 Honours) 1979 - 1989 University of Adelaide, Adelaide Australia Bachelor of Science -
Research Interests
-
Journals
Year Citation 2025 Bellas, O. M., Cao, K., Bowen, J., Smid, S., Shakib, S., Crawford, G. B., . . . Wardill, H. R. (2025). Medicinal CANnabis (CBD/THC) to prevent the symptoms and side effects of chemotherapy in people with advanced CANcer (CANCAN): protocol for a phase II, randomised, double-blind, placebo-controlled trial. BMJ Open, 15(3), e089336-1-e089336-10.
Scopus12025 Kamonsuwan, K., Kaewpradup, T., Chusak, C., Charoensiddhi, S., Smid, S., & Adisakwattana, S. (2025). β-Glucosidase-pretreated black goji berry tea reduces glucose release and enhances bile acid binding co-digestion with high-fat meals in simulated digestion. Scientific Reports, 15(1), 12 pages.
2024 Kamonsuwan, K., Balmori, V., Marnpae, M., Chusak, C., Thilavech, T., Charoensiddhi, S., . . . Adisakwattana, S. (2024). Black Goji Berry (Lycium ruthenicum) Juice Fermented with Lactobacillus rhamnosus GG Enhances Inhibitory Activity against Dipeptidyl Peptidase-IV and Key Steps of Lipid Digestion and Absorption.. Antioxidants (Basel), 13(6), 20 pages.
Scopus7 Europe PMC42024 Marsh, D. T., & Smid, S. D. (2024). Selected phytocannabinoids inhibit SN-38- and cytokine-evoked increases in epithelial permeability and improve intestinal barrier function in vitro.. Toxicol In Vitro, 99, 105888.
2024 Marsh, D. T., Shibuta, M., Kato, R., & Smid, S. D. (2024). Medicinal cannabis extracts are neuroprotective against Aβ1-42-mediated toxicity in vitro.. Basic Clin Pharmacol Toxicol, 135(5), 575-592.
Scopus2 Europe PMC22024 Staton Laws Iii, J., & Smid, S. D. (2024). Sesquiterpene-evoked phytochemical toxicity in PC12 neuronal cells reveals a variable degree of oxidative stress and alpha-tocopherol and glutathione-dependent protection.. Curr Res Toxicol, 6, 100144.
Scopus2 Europe PMC12023 Marsh, D. T., Sugiyama, A., Imai, Y., Kato, R., & Smid, S. D. (2023). The structurally diverse phytocannabinoids cannabichromene, cannabigerol and cannabinol significantly inhibit amyloid β‐evoked neurotoxicity and changes in cell morphology in PC12 cells. Basic & Clinical Pharmacology & Toxicology, 134(3), 293-309.
Scopus9 WoS1 Europe PMC62023 Wardill, H. R., Wooley, L. T., Bellas, O. M., Cao, K., Cross, C. B., van Dyk, M., . . . Price, T. J. (2023). Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges. British Journal of Cancer, 130(1), 19-30.
Scopus4 Europe PMC42023 Laws, J. S., & Smid, S. D. (2023). Characterizing cannabis-prevalent terpenes for neuroprotection reveal a role for α and β-pinenes in mitigating amyloid β-evoked neurotoxicity and aggregation in vitro.. Neurotoxicology, 100, 16-24.
Scopus6 Europe PMC32022 Laws III, J. S., Shrestha, S., & Smid, S. D. (2022). Cannabis terpenes display variable protective and anti-aggregatory actions against neurotoxic β amyloid in vitro: highlighting the protective bioactivity of α-bisabolol in motorneuronal-like NSC-34 cells. NeuroToxicology, 90, 81-87.
Scopus10 WoS3 Europe PMC32022 Shrestha, S., Choi, J. S., Zhang, W., & Smid, S. D. (2022). Neuroprotective activity of macroalgal fucofuroeckols against amyloid β peptide-induced cell death and oxidative stress. International Journal of Food Science and Technology, 57(7), 4286-4295.
Scopus5 WoS12022 Marsh, D. T., & Smid, S. D. (2022). The semi-synthetic flavonoid 2′,3′,4′-trihydroxyflavone (2-D08) inhibits both SN-38- and cytokine-evoked increases in epithelial barrier permeability in an in vitro intestinal mucositis model. Food and Function, 13(21), 11142-11152.
Scopus1 Europe PMC12022 Laws III, J., & Smid, S. D. (2022). Evaluating Cannabis sativa L.'s neuroprotection potential: From bench to bedside.. Phytomedicine, 107, 1-12.
Scopus12 WoS2 Europe PMC52021 Shrestha, S., Zhang, W., & Smid, S. D. (2021). Phlorotannins: A review on biosynthesis, chemistry and bioactivity. Food Bioscience, 39, 100832-1-100832-11.
Scopus104 WoS552021 Shrestha, S., Johnston, M. R., Zhang, W., & Smid, S. D. (2021). A phlorotannin isolated from Ecklonia radiata, Dibenzodioxin-fucodiphloroethol, inhibits neurotoxicity and aggregation of β-amyloid. Phytomedicine Plus, 1(4), 100125-1-100125-9.
Scopus152021 Dos Reis Franco, G., Smid, S., & Viegas, C. (2021). Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases.. Current neuropharmacology, 19(4), 449-464.
Scopus29 WoS7 Europe PMC182020 Marsh, D. T., & Smid, S. D. (2020). Cannabis Phytochemicals: A Review of Phytocannabinoid Chemistry and Bioactivity as Neuroprotective Agents. AUSTRALIAN JOURNAL OF CHEMISTRY, 74(6), 388-404.
Scopus14 WoS62020 Jovcevski, B., Das, S., Smid, S., & Pukala, T. L. (2020). Polyphenol honokiol and flavone 2′,3′,4′-trihydroxyflavone differentially interact with α-synuclein at distinct phases of aggregation. ACS Chemical Neuroscience, 11(24), 4469-4477.
Scopus17 WoS9 Europe PMC82020 Gunasegaran, B., Neilsen, P. M., & Smid, S. D. (2020). P53 activation suppresses irinotecan metabolite SN-38-induced cell damage in non-malignant but not malignant epithelial colonic cells.. Toxicol In Vitro, 67, 104908.
Scopus4 WoS3 Europe PMC32020 Shrestha, S., Zhang, W., Begbie, A. J., Pukala, T. L., & Smid, S. D. (2020). Ecklonia radiata extract containing eckol protects neuronal cells against Aβ1-42 evoked toxicity and reduces aggregate density.. Food Funct, 11(7), 6509-6516.
Scopus15 WoS5 Europe PMC72020 Alghazwi, M., Charoensiddhi, S., Smid, S., & Zhang, W. (2020). Impact of Ecklonia radiata extracts on the neuroprotective activities against amyloid beta (Aβ<inf>1-42</inf>) toxicity and aggregation. Journal of Functional Foods, 68, 9 pages.
Scopus25 WoS142019 Eggers, C., Fujitani, M., Kato, R., & Smid, S. (2019). Novel cannabis flavonoid, cannflavin A displays both a hormetic and neuroprotective profile against amyloid β-mediated neurotoxicity in PC12 cells: Comparison with geranylated flavonoids, mimulone and diplacone.. Biochemical pharmacology, 169, 113609.
Scopus44 WoS22 Europe PMC212019 Das, S., & Smid, S. D. (2019). Small molecule diketone flavorants diacetyl and 2,3-pentanedione promote neurotoxicity but inhibit amyloid β aggregation. Toxicology Letters, 300, 67-72.
Scopus9 WoS4 Europe PMC32019 Alghazwi, M., Smid, S., Karpiniec, S., & Zhang, W. (2019). Comparative study on neuroprotective activities of fucoidans from Fucus vesiculosus and Undaria pinnatifida. International Journal of Biological Macromolecules, 122, 255-264.
Scopus41 WoS23 Europe PMC202019 Alghazwi, M., Smid, S., Musgrave, I., & Zhang, W. (2019). In vitro studies of the neuroprotective activities of astaxanthin and fucoxanthin against amyloid beta (Aβ₁−₄₂) toxicity and aggregation. Neurochemistry International, 124, 215-224.
Scopus85 WoS66 Europe PMC512019 Li, X., Smid, S. D., Lin, J., Gong, Z., Chen, S., You, F., . . . Jin, X. (2019). Neuroprotective and anti-amyloid β effect and main chemical profiles of white tea: Comparison against green, oolong and Black tea. Molecules, 24(10), 1-15.
Scopus36 WoS14 Europe PMC112018 Alghazwi, M., Smid, S., & Zhang, W. (2018). In vitro protective activity of South Australian marine sponge and macroalgae extracts against amyloid beta (Aβ₁−₄₂) induced neurotoxicity in PC-12 cells. Neurotoxicology and Teratology, 68, 72-83.
Scopus7 WoS5 Europe PMC32018 Das, S., Pukala, T., & Smid, S. (2018). Exploring the structural diversity in inhibitors of α-Synuclein amyloidogenic folding, aggregation, and neurotoxicity. Frontiers in Chemistry, 6(MAY), 181-1-181-12.
Scopus24 WoS18 Europe PMC142018 Hofma, B., Wardill, H., Mavrangelos, C., Campaniello, M., Dimasi, D., Bowen, J., . . . Hughes, P. (2018). Colonic migrating motor complexes are inhibited in acute tri-nitro benzene sulphonic acid colitis. PLoS ONE, 13(6), e0199394-1-e0199394-15.
Scopus15 WoS13 Europe PMC112017 Das, S., & Smid, S. (2017). Identification of dibenzyl imidazolidine and triazole acetamide derivatives through virtual screening targeting amyloid beta aggregation and neurotoxicity in PC12 cells. European Journal of Medicinal Chemistry, 130, 354-364.
Scopus19 WoS14 Europe PMC62017 Marsh, D., Das, S., Ridell, J., & Smid, S. (2017). Structure-activity relationships for flavone interactions with amyloid β reveal a novel anti-aggregatory and neuroprotective effect of 2′,3′,4′-trihydroxyflavone (2-D08). Bioorganic and Medicinal Chemistry, 25(14), 3827-3834.
Scopus36 WoS28 Europe PMC132017 Campaniello, M. A., Mavrangelos, C., Eade, S., Harrington, A. M., Blackshaw, L. A., Brierley, S. M., . . . Hughes, P. A. (2017). Acute colitis chronically alters immune infiltration mechanisms and sensory neuro-immune interactions.. Brain, Behavior, and Immunity, 60, 319-332.
Scopus18 WoS15 Europe PMC122016 Gibson, R., Coller, J., Wardill, H., Hutchinson, M., Smid, S., & Bowen, J. (2016). Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Supportive Care in Cancer, 24(5), 2251-2258.
Scopus21 WoS20 Europe PMC142016 Das, S., Stark, L., Musgrave, I., Pukala, T., & Smid, S. (2016). Bioactive polyphenol interactions with β amyloid: a comparison of binding modelling, effects on fibril and aggregate formation and neuroprotective capacity. Food & Function, 7(2), 1138-1146.
Scopus45 WoS39 Europe PMC172016 Safdari, B., Sia, T., Wattchow, D., & Smid, S. (2016). Effects of pro-inflammatory cytokines, lipopolysaccharide and COX-2 mediators on human colonic neuromuscular function and epithelial permeability. Cytokine, 83, 231-238.
Scopus19 WoS13 Europe PMC112016 Alghazwi, M., Kan, Y., Zhang, W., Gai, W., Garson, M., & Smid, S. (2016). Neuroprotective activities of natural products from marine macroalgae during 1999–2015. Journal of Applied Phycology, 28(6), 3599-3616.
Scopus49 WoS412014 Janefjord, E., Maag, J., Harvey, B., & Smid, S. (2014). Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cellular and Molecular Neurobiology, 34(1), 31-42.
Scopus108 WoS81 Europe PMC672014 Harvey, B., Sia, T., Wattchow, D., & Smid, S. (2014). Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. Cytokine, 65(2), 236-244.
Scopus29 WoS21 Europe PMC182013 Wong, D., Musgrave, I., Harvey, B., & Smid, S. (2013). Açaí (Euterpe oleraceae Mart.) berry extract exerts neuroprotective effects against β-amyloid exposure in vitro. Neuroscience Letters, 556, 221-226.
Scopus50 WoS38 Europe PMC292013 Harvey, B., Nicotra, L., Vu, M., & Smid, S. (2013). Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. Cytokine (Online), 63(2), 209-217.
Scopus31 WoS25 Europe PMC252013 Nicotra, L., Vu, M., Harvey, B., & Smid, S. (2013). Prostaglandin ethanolamides attenuate damage in a human explant colitis model. Prostaglandins & Other Lipid Mediators, 100(1), 22-29.
Scopus20 WoS16 Europe PMC132012 Smid, S., Maag, J., & Musgrave, I. (2012). Dietary polyphenol-derived protection against neurotoxic β-amyloid protein: from molecular to clinical. Food & Function: linking the chemistry and physics of food with health and nutrition, 3(12), 1242-1250.
Scopus59 WoS47 Europe PMC292012 Harvey, B., Ohlsson, K., Maag, J., Musgrave, I., & Smid, S. (2012). Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. Neurotoxicology, 33(1), 138-146.
Scopus70 WoS57 Europe PMC472012 Harvey, B., & Smid, S. (2012). The gastrointestinal endocannabinoid system in health and inflammation. Current Topics in Pharmacology, 16(1), 107-118.
Scopus12011 Harvey, B., Musgrave, I., Ohlsson, K., Fransson, A., & Smid, S. (2011). The green tea polyphenol (−)-epigallocatechin-3-gallate inhibits amyloid-β evoked fibril formation and neuronal cell death in vitro. Food Chemistry, 129(4), 1729-1736.
Scopus41 WoS34 Europe PMC142009 Smid, S. (2009). Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides. Clinical Ophthalmology (online), 3(1), 663-670.
Scopus16 WoS13 Europe PMC92009 Smid, S., & Svensson, K. (2009). Inhibition of cyclooxygenase-2 and EP₁ receptor antagonism reduces human colonic longitudinal muscle contractility in vitro. Prostaglandins & Other Lipid Mediators, 88(3-4), 117-121.
Scopus14 WoS11 Europe PMC122008 Smid, S. (2008). Gastrointestinal endocannabinoid system: Multifaceted roles in the healthy and inflamed intestine. Clinical and Experimental Pharmacology and Physiology, 35(11), 1383-1387.
Scopus16 WoS12 Europe PMC92007 Smid, S., Bjorklund, C., Svensson, K., Heigis, S., & Revesz, A. (2007). The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon. European Journal of Pharmacology, 575(1-3), 168-176.
Scopus29 WoS22 Europe PMC172006 Hinds, N., Ullrich, K., & Smid, S. (2006). Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. British Journal of Pharmacology, 148(2), 191-199.
Scopus57 WoS48 Europe PMC482005 Smith, A., & Smid, S. (2005). Impaired capsaicin and neurokinin-evoked colonic motility in inflammatory bowel disease. Journal of Gastroenterology and Hepatology, 20(5), 697-704.
Scopus30 WoS28 Europe PMC262002 Lehmann, A., Blackshaw, L., Branden, L., Carlsson, A., Jensen, J., Nygren, E., & Smid, S. (2002). Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology, 123(4), 1129-1134.
Scopus92 WoS65 Europe PMC572002 Lehmann, A., Blackshaw, L. A., Branden, L., Carlsson, A., Jensen, J., Nygren, E., & Smid, S. D. (2002). Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs (vol 123, pg 1129, 2002). GASTROENTEROLOGY, 123(6), 2162-2163. 2002 Lehmann, A., Blackshaw, L. A., Branden, L., Carlsson, A., Jensen, J., Nygren, E., & Smid, S. D. (2002). Erratum: Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs (Gastroenterology (2002) 123 (1129-1134)). Gastroenterology, 123(6), 2162-2163.
2001 Smid, S., Young, R., Isaacs, N., & Blackshaw, L. (2001). GABABR expressed on vagal afferent neurones inhibit gastric mechanosensitivity in ferret proximal stomach. American Journal of Physiology - Gastrointestinal and Liver Physiology, 281(6), G1494-G1501.
Scopus67 WoS48 Europe PMC442001 Smid, S. D., & Blackshaw, L. A. (2001). GABA<sub>B</sub> receptors inhibit vagal afferent mechanoreceptor responses to gastric distension.. GASTROENTEROLOGY, 120(5), A5-A6. 2000 Smid, S. D., & Blackshaw, L. A. (2000). Ganglionic and neuroeffector transmission to the ferret lower esophageal sphincter in a novel <i>in vitro</i> oesophagogastric preparation.. GASTROENTEROLOGY, 118(4), A155.
2000 Blackshaw, L., Smid, S., Dent, J., & O'Donnell, T. (2000). GABAB receptor-mediated effects on vagal pathways to the lower oesophageal sphincter and heart. British Journal of Pharmacology, 130(2), 279-288.
Scopus43 WoS35 Europe PMC322000 Staunton, E., Smid, S., Dent, J., & Blackshaw, L. (2000). Triggering of transient LES relaxations in ferrets: role of sympathetic pathways and effects of baclofen. American Journal of Physiology-Gastrointestinal and Liver Physiology, 279(1 42-1), G157-G162.
Scopus45 WoS33 Europe PMC282000 Blackshaw, L., Page, A., Smid, S., Dent, J., & Lehmann, A. (2000). GABAB receptors - peripheral and central targets for controlling gastroesophageal reflux. Current Opinion in Central & Peripheral Nervous System Investigational Drugs, 2(3), 333-343.
Scopus62000 Smid, S., & Blackshaw, L. (2000). Neuromuscular function of the human lower oesophageal sphincter in reflux disease and Barrett's oesophagus. Gut, 46(6), 756-761.
Scopus19 WoS16 Europe PMC112000 Smid, S., & Blackshaw, L. (2000). Vagal neurotransmission to the ferret lower oesophageal sphincter: inhibition via GABAB receptors. British Journal of Pharmacology, 131(3), 624-630.
Scopus26 WoS21 Europe PMC172000 Smid, S., & Blackshaw, L. (2000). Vagal ganglionic and nonadrenergic noncholinergic neurotransmission to the ferret lower oesophageal sphincter. Autonomic Neuroscience-Basic & Clinical, 86(1-2), 30-36.
Scopus6 WoS5 Europe PMC51999 Blackshaw, L. A., Smid, S. D., Smid, S. D., O'Donnell, T. A., & Dent, J. (1999). GABA<sub>B</sub> receptors inhibit vagal influence on the lower oesophageal sphincter (LOS). GASTROENTEROLOGY, 116(4), A960.
WoS41998 Smid, S. D., Page, A. J., O'Donnell, T., Langman, J., Rowland, R., & Blackshaw, L. A. (1998). Oesophagitis-induced changes in capsaicin-sensitive tachykininergic pathways in the ferret lower oesophageal sphincter. Neurogastroenterology and Motility, 10(5), 403-411.
Scopus15 WoS11 Europe PMC111998 Smid, S. D., Lynn, P. A., Templeman, R., & Blackshaw, L. A. (1998). Activation of non-adrenergic non-cholinergic inhibitory pathways by endogenous and exogenous tachykinins in the ferret lower oesophageal sphincter. Neurogastroenterology and Motility, 10(2), 149-156.
Scopus17 WoS15 Europe PMC121998 Smid, S. D., Dent, J., & Blackshaw, L. A. (1998). In vitro function of the human lower esophageal sphincter (LES) in Barrett's esophagus. GASTROENTEROLOGY, 114(4), A289.
1997 Smid, S. D., Page, A. J., ODonnell, T., & Blackshaw, L. A. (1997). Altered functional innervation of the ferret lower oesophageal sphincter (LOS) in oesophagitis.. GASTROENTEROLOGY, 112(4), A828. 1995 Smid, S., Frewin, D., Wyartt, C., & Head, R. (1995). Functional tolerance to a-adrenergic receptor blockade in the spontaneously hypertensive rat highlights the multi-functional role of vascular angiotensin II in the development of hypertension. Journal of Vascular Research, 32(4), 247-253.
Scopus6 WoS4 Europe PMC41993 Jonsson, J. R., Smid, S. D., Frewin, D. B., & Head, R. J. (1993). Angiotensin II-mediated facilitation of sympathetic neurotransmission in the spontaneously hypertensive rat is not associated with neuronal uptake of the peptide. Journal of Cardiovascular Pharmacology, 22(5), 750-753.
Scopus17 WoS14 Europe PMC10 -
Book Chapters
Year Citation 2023 Laws III, J. S., Shrestha, S., & Smid, S. D. (2023). Cannabis terpenes as neuroprotective agents: A focus on α-bisabolol. In V. R. Preedy, V. B. Patel, & C. R. Martin (Eds.), Medicinal Usage of Cannabis and Cannabinoids (pp. 207-215). Elsevier.
DOI2014 Das, S., & Smid, S. (2014). The Antiaggregative, Antiamyloid Properties of Bioactive Polyphenols in the Treatment of Alzheimer's Disease. In R. Watson (Ed.), Bioactive Nutraceuticals and Dietary Supplements in Neurological and Brain Disease: Prevention and Therapy (pp. 73-76). United Kingdom: Academic Press.
DOI Scopus22013 Smid, S., & Musgrave, I. (2013). Dietary polyphenols as inhibitors of Β-amyloid-evoked neurotoxicity: implications for the treatment of Alzheimer's disease. In J. Sun, K. Prasad, A. Ismail, B. Yang, X. You, & L. Li (Eds.), Polyphenols: Chemistry, Dietary Sources and Health Benefits (1 ed., pp. 521-538). United States: Nova Science Publishers. 2009 Smid, S. (2009). Neuronal mechanosensitivity in the gastrointestinal tract. In A. Kamkin, I. Kiseleva, N. Tavernarakis, & P. Persson (Eds.), Mechanosensitivity of the nervous system (pp. 87-106). Russia: Springer.
DOI -
Conference Papers
Year Citation 2023 Smid, S., Shrestha, S., Choi, J. -S., & Zhang, W. (2023). Innate immunomodulatory actions of macroalgal phlorotannins: In vitro modulation of intestinal barrier function and epithelial ACE-2 expression. In BRITISH JOURNAL OF PHARMACOLOGY Vol. 180 (pp. 818-819). WILEY. 2015 Smid, S., Das, S., Musgrave, I., & Pukala, T. (2015). Bioactive polyphenol interactions with β amyloid: a comparison of binding, fibril inhibition and neuroprotection. In JOURNAL OF NEUROCHEMISTRY Vol. 134 (pp. 363-364). Cairns, AUSTRALIA: WILEY-BLACKWELL. 2002 Smith, A., & Smid, S. D. (2002). Effects of inflammatory bowel disease on human colonic neuromuscular function <i>in vitro</i>.. In GASTROENTEROLOGY Vol. 122 (pp. A319). W B SAUNDERS CO. 2002 Smid, S. D., & Blackshaw, L. A. (2002). Histamine 3 receptors inhibit vagal afferent mechanoreceptors in the ferret proximal stomach.. In GASTROENTEROLOGY Vol. 122 (pp. A140). W B SAUNDERS CO. 1991 HEAD, R. J., SMID, S. D., MANO, M., JONSSON, J. R., & FREWIN, D. B. (1991). CAPTOPRIL TREATMENT REVERSES THE ENHANCED CONCENTRATION OF 3-METHYLHISTIDINE IN RESISTANCE AND CONDUCTING VESSELS IN THE SPONTANEOUSLY HYPERTENSIVE RAT. In M. J. MULVANY, N. C. B. NYBORG, C. AALKJAER, S. STRANDGAARD, & A. M. HEAGERTY (Eds.), RESISTANCE ARTERIES, STRUCTURE AND FUNCTION Vol. 974 (pp. 325-328). DENMARK, REBILD: ELSEVIER SCIENCE PUBL B V. -
Conference Items
Grants and Funding
Research Support and Scholarship
| 2024 | Principal Investigator. Investigating the mechanisms of vaping associated lung injury from medicinal cannabis. MAWA Trust Research Grant | $AUD 20,000 |
| 2022 | Principal Investigator. Marine-derived bioactives and nutraceuticals: Sustainable use of marine products for health and wellbeing. AC21 Special Project Funding | $USD 15,000 |
| 2021 | Co-Investigator. Exploring the use of personalised CBD/THC dosing to prevent common and impactful symptoms of treatment in advanced cancer. The CANnabinoids for CANcer Therapy (CANCAN) Clinical Trial: Medical Research Futures Fund, Department of Health, Australian Goverment. | $AUD $1.5M |
| 2019 | Principal Investigator. Australia Japan Foundation Award, Dept Foreign Affairs and Trade. Enabling technologies in Personalised and Precision Medicine. | $AUD 38,600 |
| 2018 | JSPS Invitational Fellowship, Nagoya University. Development of Super-efficient Screening Technologies for Neural Cell Regulatory Products. |
¥JPY 342,000 |
| 2018 | Principal Investigator. Faculty Research Infrastructure Award. The University of Adelaide. | AUD $17,000 |
| 2017-18 | Principal Investigator. Faculty Research Development Award (with Prof Kato, Nagoya University and Dr Ian Musgrave). Novel neuroprotective agents targeting beta amyloid. The University of Adelaide. | AUD $15,500 |
| 2013-15 | Co-Investigator (with Ian Musgrave, Louise O’Keefe and Tara Pukala). 'Structure function relationships of anti-amyloid drugs: verification in an in-vivo model.' lnterdisciplinary Research Fund Grant, The University of Adelaide. | AUD $21,000 |
| 2011-13 | Principal Investigator. (Associate Investigator: Dr Rachel Gibson). Validation of an ex vivo human colonic mucosal explant colitis model. MAWA Trust Research Grant. | AUD $28,122 |
| 2010-12 | Principal Investigator Broad Medical Research Program, United States (IBD-0268R). Functional Expression of the Endocannabinoid System in Inflammatory Bowel Disease. | USD $130,000 |
Teaching and Course Coordination
| 2006-present | The University of Adelaide: Course Coordinator - PHARM 3102 Drug Discovery & Development; HLTH SC 2100 Fundamentals of Human Nutrition. Courses taught: Pharmacology 2100/2200 (Level 2 B.Hlth.Sci, B. Pharm. Eng.). Pharmacology for Nursing (Level 1&2, Bachelor of Nursing). PHARM 3101, 3102, 3103, HLTH SC 2100, 2103, 2104, 3100. Higher Degree by Research: Discipline Coordinator |
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2024 Principal Supervisor In vitro neuroprotective effects of alpha-1 adrenoceptor antagonists Doctor of Philosophy Doctorate Full Time Mr Aari Jasper Oliphant-Hand 2022 Co-Supervisor Diagnosis and therapeutics of intrinsically disordered protein misfolding disorders Doctor of Philosophy Doctorate Full Time Mr Zohaib Raza 2022 Principal Supervisor The bioprotective properties of cannabis phytochemicals on mammalian cells Doctor of Philosophy Doctorate Full Time Mr Luke Thomas Wooley -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2022 - 2024 Principal Supervisor Characterizing the Neurological Bioactivity of Cannabis Phytochemicals Doctor of Philosophy Doctorate Full Time Mr John Laws III 2019 - 2022 Principal Supervisor Characterising the Protective Bioactivity of Macroalgal Polyphenols Doctor of Philosophy Doctorate Full Time Mr Srijan Shrestha 2017 - 2022 Principal Supervisor Exploring the Bioactivity and Therapeutic Potential of Structurally Diverse Phytochemicals in Neurodegenerative and Gastrointestinal Disease Doctor of Philosophy Doctorate Full Time Mr Dylan Thomas Marsh 2016 - 2020 Co-Supervisor Visualising Intestinal Inflammation and Fibrosis using Zirconium-89 Labelled Antibodies in a Preclinical Model of Inflammatory Bowel Disease Doctor of Philosophy Doctorate Full Time Miss Nicole Dmochowska 2015 - 2018 Principal Supervisor Small molecular inhibitors of Amyloid beta and alpha Synuclein amyloidogenic aggregation, toxicity and in silico design of amyloid-binding ligands Doctor of Philosophy Doctorate Full Time Mrs Sukanya Das 2010 - 2014 Principal Supervisor The Effect of Cannabinoids on Cytokine Evoked Human Colonic Mucosal Damage and Caco-2 Epithelial Permeability Doctor of Philosophy Doctorate Full Time Mr Benjamin Harvey
-
Board Memberships
Date Role Board name Institution name Country 2015 - ongoing Advisory Board Member Scientific Advisory Board LeafCann Pty Ltd Australia -
Committee Memberships
Date Role Committee Institution Country 2009 - ongoing Member Scientific Organising Committee, Annual National Symposia: Urogenital and Gastrointestinal Research - - -
Memberships
Date Role Membership Country 2017 - ongoing Member Australia New Zealand Marine Biotechnology Society Australia 2016 - ongoing Member International Cannabinoid Research Society - 2014 - ongoing Member International Society for Neurochemistry - 2014 - ongoing - International Society for Neurochemistry - 2006 - ongoing - International Cannabinoid Research Society - 1991 - ongoing Member Australasian Society for Clinical and Experimental Pharmacology and Toxicology - 1991 - ongoing - Australasian Society of Clinical and Experimental Pharmacology and Toxicology (ASCEPT). - -
Consulting/Advisories
Date Institution Department Organisation Type Country 2015 - ongoing LeafCann Australia Pty Ltd - - - -
Editorial Boards
Date Role Editorial Board Name Institution Country 2013 - ongoing Board Member Clinical and Experimental Physiology and Pharmacology Journal - - 2012 - ongoing Editor CEPP journal - - -
Industry Partnerships
Date Engagement Type Partner Name 2016 - ongoing Consultant CSIRO Materials Division
Connect With Me
External Profiles
